Duvelisib

Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. It is taken by mouth. It is a PI3 kinase inhibitor.

Common side effects include diarrhea, low white blood cells, rash, feeling tired, fever, and muscle pains. Other serious side effects include inflammation of the lungs and infections. It is a dual inhibitor of PI3Kδ and PI3Kγ.

Duvelisib is indicated to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior therapies that did not work or stopped working. CLL is a type of cancer that begins in the white blood cells, and SLL is a type of cancer that begins mostly in the lymph nodes.

Duvelisib may cause infections, diarrhea, inflammation of the intestines and lungs, skin reactions, and high liver enzyme levels in the blood.

Patients taking duvelisib may have a higher risk of death.

Duvelisib is a Phosphoinositide 3-kinase inhibitor, specifically of the delta and gamma isoforms of PI3K. This class of compounds works by preventing PI3K from playing its role in transducing signals from outside of cells into various intracellular pathways involved in cell cycle regulation, apoptosis, DNA repair, senescence, angiogenesis and cell metabolism, including the PI3K/AKT/mTOR pathway.

Duvelisib, also known as IPI-145, was discovered by Intellikine, a company founded in September 2007 based on biochemistry research from the lab of Kevan Shokat at the University of California San Francisco.

In mid-June 2016, Infinity announced results of Phase II clinical trial of duvelisib.